help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abramson, M. J.
Right arrow Articles by Weiner, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abramson, M. J.
Right arrow Articles by Weiner, J. M.

Am. J. Respir. Crit. Care Med., Vol 151, No. 4, Apr 1995, 969-974.

Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials

MJ Abramson, RM Puy and JM Weiner
Department of Social and Preventive Medicine, Monash Medical School, Alfred Hospital, Melbourne, Australia.

A meta-analysis of clinical trials of allergen immunotherapy was undertaken to assess the efficacy of this controversial form of therapy in asthma. A computerized bibliographic search revealed 20 randomized placebo controlled double-blind trials of allergen immunotherapy for asthma. The results extracted included asthmatic symptoms, medication requirements, lung function, and bronchial hyperreactivity (BHR). Categorical outcomes were expressed as odds ratios and continuous outcomes as effect sizes. The combined odds of symptomatic improvement from immunotherapy with any allergen were 3.2 (95% CI 2.2 to 4.9). The odds for reduction in medication after mite immunotherapy were 4.2 (95% CI 2.2 to 7.9). The combined odds for reduction in BHR were 6.8 (95% CI 3.8 to 12.0). The mean effect size for any allergen immunotherapy on all continuous outcomes was 0.71 (95% CI 0.43 to 1.00), which would correspond to a mean 7.1% predicted improvement in FEV1 from immunotherapy. Although the benefits of allergen immunotherapy could be overestimated because of unpublished negative studies, an additional 33 such studies would be necessary to overturn these results. Allergen immunotherapy is a treatment option in highly selected patients with extrinsic ("allergic") asthma.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. A. Taher, B. C. A. M. van Esch, G. A. Hofman, P. A. J. Henricks, and A. J. M. van Oosterhout
1{alpha},25-Dihydroxyvitamin D3 Potentiates the Beneficial Effects of Allergen Immunotherapy in a Mouse Model of Allergic Asthma: Role for IL-10 and TGF-{beta}
J. Immunol., April 15, 2008; 180(8): 5211 - 5221.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. G. Shojania, M. Sampson, M. T. Ansari, J. Ji, S. Doucette, and D. Moher
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Ann Intern Med, August 21, 2007; 147(4): 224 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
M. A. Finkelman, S. J. Lempitski, and J. E. Slater
{beta}-Glucans in standardized allergen extracts
Innate Immunity, August 1, 2006; 12(4): 241 - 245.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. J. Holtzman
Drug Development for Asthma
Am. J. Respir. Cell Mol. Biol., August 1, 2003; 29(2): 163 - 171.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
K. Kitagaki, V. V. Jain, T. R. Businga, I. Hussain, and J. N. Kline
Immunomodulatory Effects of CpG Oligodeoxynucleotides on Established Th2 Responses
Clin. Vaccine Immunol., November 1, 2002; 9(6): 1260 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Chinn
Comparing and combining studies of bronchial responsiveness
Thorax, May 1, 2002; 57(5): 393 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Franklin Adkinson Jr.
Con: Immunotherapy Is Not Clinically Indicated in the Management of Allergic Asthma
Am. J. Respir. Crit. Care Med., December 15, 2001; 164(12): 2140 - 2141.
[Full Text] [PDF]

Home page
 NEJMHome page
W. W. Busse and R. F. Lemanske
Asthma
N. Engl. J. Med., February 1, 2001; 344(5): 350 - 362.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Janssen, A. J. M. van Oosterhout, F. P. Nijkamp, W. van Eden, and M. H. M. Wauben
The Efficacy of Immunotherapy in an Experimental Murine Model of Allergic Asthma Is Related to the Strength and Site of T Cell Activation During Immunotherapy
J. Immunol., December 15, 2000; 165(12): 7207 - 7214.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. D. GREMBIALE, L. CAMPOROTA, S. NATY, C. M. E. TRANFA, R. DJUKANOVIC, and S. A. MARSICO
Effects of Specific Immunotherapy in Allergic Rhinitic Individuals with Bronchial Hyperresponsiveness
Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2048 - 2052.
[Abstract] [Full Text]

Home page
 JAMAHome page
W. W. Busse
A 47-Year-Old Woman With Severe Asthma
JAMA, November 1, 2000; 284(17): 2225 - 2233.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Casale
Immunobiology of Asthma and Rhinitis . Pathogenic Factors and Therapeutic Options
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1778 - 1787.
[Full Text]

Home page
 CMAJHome page
Immunotherapy
Can. Med. Assoc. J., November 1, 1999; 161(90111): s21 - 23.
[Full Text]

Home page
 NEJMHome page
S. R. Durham, S. M. Walker, E.-M. Varga, M. R. Jacobson, F. O'Brien, W. Noble, S. J. Till, Q. A. Hamid, and K. T. Nouri-Aria
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
N. Engl. J. Med., August 12, 1999; 341(7): 468 - 475.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Broide, J. Schwarze, H. Tighe, T. Gifford, M.-D. Nguyen, S. Malek, J. Van Uden, E. Martin-Orozco, E. W. Gelfand, and E. Raz
Immunostimulatory DNA Sequences Inhibit IL-5, Eosinophilic Inflammation, and Airway Hyperresponsiveness in Mice
J. Immunol., December 15, 1998; 161(12): 7054 - 7062.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. J. M. Van Oosterhout, B. Van Esch, G. Hofman, C. L. Hofstra, I. Van Ark, F. P. Nijkamp, M. L. Kapsenberg, H. F. J. Savelkoul, and F. R. Weller
Allergen Immunotherapy Inhibits Airway Eosinophilia and Hyperresponsiveness Associated with Decreased IL-4 Production by Lymphocytes in a Murine Model of Allergic Asthma
Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 622 - 628.
[Abstract] [Full Text]

Home page
 PediatricsHome page
B. B. Wray
No Evidence-based Medicine
Pediatrics, April 1, 1998; 101(4): 729 - 729.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
J. N. Kline, T. J. Waldschmidt, T. R. Businga, J. E. Lemish, J. V. Weinstock, P. S. Thorne, and A. M. Krieg
Cutting Edge: Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a Murine Model of Asthma
J. Immunol., March 15, 1998; 160(6): 2555 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. B. Wray, R. E. Coifman, B. R. Gordon, A. Des Roches, L. Paradis, J. Paradis, J. Bousquet, F.-B. Michel, H.-J. Malling, J. T. Marino, et al.
Immunotherapy for Asthma
N. Engl. J. Med., June 26, 1997; 336(26): 1911 - 1913.
[Full Text]

Home page
 NEJMHome page
N. F. Adkinson, P. A. Eggleston, D. Eney, E. O. Goldstein, K. C. Schuberth, J. R. Bacon, R. G. Hamilton, M. E. Weiss, H. Arshad, C. L. Meinert, et al.
A Controlled Trial of Immunotherapy for Asthma in Allergic Children
N. Engl. J. Med., January 30, 1997; 336(5): 324 - 332.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Weiner, M. Abramson, R. Puy, J. Wilson, J. M. Portnoy, I. Finegold, T. A.E. Platts-Mills, J. S. Klein, F. Chmelik, A. Doughty, et al.
Ragweed Immunotherapy in Adult Asthma
N. Engl. J. Med., July 18, 1996; 335(3): 203 - 206.
[Full Text]

Home page
 NEJMHome page
P. J. Barnes
Is Immunotherapy for Asthma Worthwhile?
N. Engl. J. Med., February 22, 1996; 334(8): 530 - 532.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1995 American Thoracic Society